Actively Recruiting
Impairments of Neuro-muscular Communication in Motor-Neuron Disease: A Bio-Marker for Early and Personalised Diagnosis
Led by University of Dublin, Trinity College · Updated on 2022-12-23
400
Participants Needed
1
Research Sites
626 weeks
Total Duration
On this page
Sponsors
U
University of Dublin, Trinity College
Lead Sponsor
M
Motor Neurone Disease Association, UK
Collaborating Sponsor
AI-Summary
What this Trial Is About
Motor neuron disease (MND) or ALS is a nervous system disease. ALS leads to a loss of movement ability that eventually leads to death. At the moment, there is no known treatment for ALS. Early diagnosis in individuals improves clinical care and facilitates timely entry into clinical trials. However, current methods for diagnosis are primarily clinical, and to date, no cost-effective biomarkers have been developed. Our objective is to identify a robust non-invasive neurophysiological-based system that can be used both as a biomarker of disease onset, and a measurement of progression using quantitative EEG and surface EMG (bipolar and high-density). The investigators postulate that analysing the joint recordings of EEG and EMG (bipolar or high-density) can give measures that better distinguish healthy people and ALS patient subgroups and that the findings can be developed as biomarkers of early diagnosis and disease progression.
CONDITIONS
Official Title
Impairments of Neuro-muscular Communication in Motor-Neuron Disease: A Bio-Marker for Early and Personalised Diagnosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Healthy volunteers matched by age and gender to patient groups
- Healthy volunteers must have intact physical ability to take part in the experiment
- Patients diagnosed with ALS, PLS, PMA, SMA, Polio, or MS
- Patients must be capable of providing informed consent
You will not qualify if you...
- Healthy controls with history of neuromuscular, neurological, or active psychiatric disease
- Healthy controls with history of reaction or allergy to recording environments, equipment, or gels
- Patients with active psychiatric disease
- Patients with medical conditions causing severe neuropathy (e.g., poorly controlled diabetes)
- Patients with history of reaction or allergy to recording environments, equipment, or gels
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Academic Unit of Neurology, Trinity College Dublin, The University of Dublin
Dublin, Leinster, Ireland, Dublin 2
Actively Recruiting
Research Team
O
Orla Hardiman, BSc MB BCh BAO MD FRCPI FAAN
CONTACT
S
Saroj Bista, MSc
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here